(Q24240057)

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Increased hepatic iron deposition resulting from treatment of chronic hepatitis C with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Modulation of hepatitis C virus quasispecies heterogeneity by interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Antiviral action of ribavirin in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Evaluation of ribavirin efficacy and tolerance in subjects with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Early ribavirin treatment and avoidance of corticosteroids in hepatitis C virus (HCV)-positive liver transplant recipients: interim report of a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Early addition of ribavirin to interferon in chronic hepatitis C not responsive to interferon monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Interferon plus ribavirin in chronic hepatitis C non-responders to recombinant alpha-interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Austrian Hepatitis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

A randomized trial of high-dose interferon alpha-2b, with or without ribavirin, in chronic hepatitis C patients who have not responded to standard dose interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Efficacy of ribavirin monotherapy following combination therapy with interferon alfa-2b and ribavirin for patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

r-Interferon alfa-2b/ribavirin combined therapy followed by low-dose r-interferon alfa-2b in chronic hepatitis C interferon nonresponders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, Franc

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

A randomized, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon-ribavirin combination therapy will enhance sustained virologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Epidemiology of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Ribavirin plus interferon versus interferon for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Teratogenic effects of ribavirin on hamster and rat embryos

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Hepatology may have problems with putative surrogate outcome measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Hepatitis C: the clinical spectrum of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Successful rescue therapy with only 4 weeks ribavirin monotherapy in end-stage cirrhosis due to genotype 2 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Prolonged therapy for hepatitis C with low-dose peginterferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Recent advances: hepatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Interferon for interferon naive patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Pure red cell aplasia induced by erythropoiesis-stimulating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Ribavirin: a possible alternative for the treatment of chronic non-A, non-B hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

Natural history of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

7 January 2021

Changes in hepatitis C virus antigen in liver with antiviral therapy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

7 January 2021

Decisions, decisions, decisions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

7 January 2021

American Gastroenterological Association medical position statement on the management of hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

7 January 2021

Molecular mechanisms of action of ribavirin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

7 January 2021

Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005527.PUB2

7 January 2021